Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Colorectal Cancer Metastatic
About this trial
This is an interventional treatment trial for Colorectal Cancer Metastatic
Eligibility Criteria
Inclusion criteria :
- Histologically or cytologically proven adenocarcinoma of the colon or rectum.
- Metastatic disease.
- Eastern Cooperative Oncology Group performance status 0-1.
- One and only one prior chemotherapeutic regimen for metastatic disease. This prior chemotherapy was an oxaliplatin containing regimen. Participants must had progressed during or after the oxaliplatin based chemotherapy. Participants relapsed within 6 months of completion of oxaliplatin adjuvant chemotherapy were eligible.
- Signed written informed consent obtained prior to inclusion.
Exclusion criteria:
- Prior therapy with irinotecan.
- Inadequate bone marrow, liver and renal function: neutrophils < 1.5x109/L, platelets < 100x109/L, hemoglobin < 9.0 g/dL, total bilirubin >1.5 x upper normal limit (ULN), transaminases >3 x ULN (unless liver metastasis are present), alkaline phosphatase >3 x ULN (unless liver metastasis are present), serum creatinine > 1.5 x ULN.
- Less than 4 weeks from prior radiotherapy, prior chemotherapy, prior major surgery (or until the surgical wound were fully healed).
- Treatment with any investigational drug within the prior 30 days.
- Treatment with concomitant anticonvulsivant agents that were CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine), unless discontinued >7 days.
- History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease.
- Prior malignancy (other than colorectal) including prior malignancy from which the participants had been disease free for < 5 years (except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix).
- Any of the following within 6 months prior to study inclusion: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, severe congestive heart failure, stroke or transient ischemic attack.
- Any of the following within 3 months prior study inclusion: severe gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.
- Occurrence of deep vein thrombosis within 4 weeks, prior to study inclusion.
- Known acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease requiring antiretroviral treatment.
- Known dihydropyrimidine dehydrogenase deficiency.
- Predisposing colonic or small bowel disorders in which the symptoms were uncontrolled.
- Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea, unresolved bowel obstruction/sub-obstruction, more than hemicolectomy, extensive small intestine resection with chronic diarrhea.
- Known Gilbert's syndrome.
- Unresolved or unstable toxicity from any prior anti cancer therapy at the time of inclusion.
- History of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with FOLFIRI (irinotecan, 5-Fluorouracil, leucovorin).
- Severe acute or chronic medical condition, which could impair the ability of the participants to participate to the study.
- Urine protein-creatinine ratio (UPCR) >1 on morning spot urinalysis or proteinuria > 500 mg/24-h.
- Uncontrolled hypertension within 3 months prior to study inclusion.
- Participants on anticoagulant therapy with unstable dose of warfarin and/or had an out-of-therapeutic range INR within the 4 weeks prior to study inclusion.
- Evidence of clinically significant bleeding predisposition or underlying coagulopathy, non-healing wound.
- Pregnant or breast-feeding women.
- Participants with reproductive potential who were not agree to use an accepted effective method of contraception.
The above information wass not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Sites / Locations
- Investigational Site Number 840-002
- Investigational Site Number 840-008
- Investigational Site Number 840-007
- Investigational Site Number 840-004
- Investigational Site Number 840-006
- Investigational Site Number 840-011
- Investigational Site Number 840-001
- Investigational Site Number 840-010
- Investigational Site Number 840-012
- Investigational Site Number 840-009
- Investigational Site Number 840-003
- Investigational Site Number 840-005
- Investigational Site Number 056010
- Investigational Site Number 056015
- Investigational Site Number 056004
- Investigational Site Number 056001
- Investigational Site Number 056012
- Investigational Site Number 056009
- Investigational Site Number 056003
- Investigational Site Number 056007
- Investigational Site Number 056014
- Investigational Site Number 056013
- Investigational Site Number 056002
- Investigational Site Number 056011
- Investigational Site Number 008
- Investigational Site Number 009
- Investigational Site Number 012
- Investigational Site Number 006
- Investigational Site Number 003
- Investigational Site Number 002
- Investigational Site Number 011
- Investigational Site Number 013
- Investigational Site Number 001
- Investigational Site Number 004
- Investigational Site Number 005
- Investigational Site Number 124002
- Investigational Site Number 124003
- Investigational Site Number 124005
- Investigational Site Number 124004
- Investigational Site Number 124006
- Investigational Site Number 124001
- Investigational Site Number 152001
- Investigational Site Number 152003
- Investigational Site Number 203005
- Investigational Site Number 203003
- Investigational Site Number 203001
- Investigational Site Number 203002
- Investigational Site Number 203004
- Investigational Site Number 203006
- Investigational Site Number 208001
- Investigational Site Number 208003
- Investigational Site Number 208002
- Investigational Site Number 246001
- Investigational Site Number 246002
- Investigational Site Number 276-016
- Investigational Site Number 276-010
- Investigational Site Number 276-011
- Investigational Site Number 276-012
- Investigational Site Number 276-009
- Investigational Site Number 276-013
- Investigational Site Number 276-004
- Investigational Site Number 276-007
- Investigational Site Number 276-003
- Investigational Site Number 276-019
- Investigational Site Number 276-008
- Investigational Site Number 276-018
- Investigational Site Number 276-014
- Investigational Site Number 276-006
- Investigational Site Number 276-001
- Investigational Site Number 276-002
- Investigational Site Number 276-015
- Investigational Site Number 276-017
- Investigational Site Number 276-005
- Investigational Site Number 276-020
- Investigational Site Number 372002
- Investigational Site Number 372004
- Investigational Site Number 372001
- Investigational Site Number 376002
- Investigational Site Number 376001
- Investigational Site Number 376005
- Investigational Site Number 376003
- Investigational Site Number 376004
- Investigational Site Number 380-005
- Investigational Site Number 380-029
- Investigational Site Number 380-021
- Investigational Site Number 380-004
- Investigational Site Number 380-007
- Investigational Site Number 380-012
- Investigational Site Number 380-019
- Investigational Site Number 380-023
- Investigational Site Number 380-001
- Investigational Site Number 380-014
- Investigational Site Number 380-016
- Investigational Site Number 380-013
- Investigational Site Number 380-015
- Investigational Site Number 380-025
- Investigational Site Number 380-022
- Investigational Site Number 380-028
- Investigational Site Number 380-017
- Investigational Site Number 380-002
- Investigational Site Number 380-008
- Investigational Site Number 380-024
- Investigational Site Number 380-010
- Investigational Site Number 380-011
- Investigational Site Number 380-006
- Investigational Site Number 380-026
- Investigational Site Number 380-020
- Investigational Site Number 380-009
- Investigational Site Number 380-003
- Investigational Site Number 380-018
- Investigational Site Number 1
- Investigational Site Number 484002
- Investigational Site Number 484009
- Investigational Site Number 484001
- Investigational Site Number 484010
- Investigational Site Number 528001
- Investigational Site Number 528002
- Investigational Site Number 578002
- Investigational Site Number 578001
- Investigational Site Number 630-001
- Investigational Site Number 643003
- Investigational Site Number 643001
- Investigational Site Number 643004
- Investigational Site Number 643005
- Investigational Site Number 643002
- Investigational Site Number 643006
- Investigational Site Number 643009
- Investigational Site Number 724016
- Investigational Site Number 724008
- Investigational Site Number 724012
- Investigational Site Number 724002
- Investigational Site Number 724013
- Investigational Site Number 724014
- Investigational Site Number 724003
- Investigational Site Number 724015
- Investigational Site Number 724005
- Investigational Site Number 724004
- Investigational Site Number 724010
- Investigational Site Number 724011
- Investigational Site Number 724006
- Investigational Site Number 724001
- Investigational Site Number 724009
- Investigational Site Number 724007
- Investigational Site Number 752_002
- Investigational Site Number 752_001
- Investigational Site Number 764005
- Investigational Site Number 764002
- Investigational Site Number 764003
- Investigational Site Number 764008
- Investigational Site Number 764001
- Investigational Site Number 764006
- Investigational Site Number 764009
- Investigational Site Number 764004
- Investigational Site Number 764010
- Investigational Site Number 764007
- Investigational Site Number 792-06
- Investigational Site Number 792-01
- Investigational Site Number 792-09
- Investigational Site Number 792-08
- Investigational Site Number 792-02
- Investigational Site Number 792010
- Investigational Site Number 792-05
- Investigational Site Number 792012
- Investigational Site Number 792-03
- Investigational Site Number 792-04
- Investigational Site Number 792-007
- Investigational Site Number 792011
- Investigational Site Number 826005
- Investigational Site Number 826011
- Investigational Site Number 826008
- Investigational Site Number 826007
- Investigational Site Number 826012
- Investigational Site Number 826003
- Investigational Site Number 826009
- Investigational Site Number 826004
- Investigational Site Number 826006
- Investigational Site Number 826002
- Investigational Site Number 826001
- Investigational Site Number 826010
Arms of the Study
Arm 1
Experimental
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.